Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.

Lembo A, Kuo B, Boinpally R, Li E, Mallick M, Bochenek W, Bartolini W

Alimentary pharmacology & therapeutics2 Nov 2022Cited by 2 (Europe PMC)

PMID36324245DOI10.1111/apt.17274PepBankPUB-36324245

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with IBS-D, MD-7246 changed abdominal pain by -1.93 versus -2.01 with placebo, without a significant difference (p > 0.05).
In plain wordsIn adults with IBS-D, pain decreased numerically less with MD-7246 than placebo, without a significant difference.
Peptide
Linaclotide
Outcome
IncreaseAbdominal pain change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
300 μg once daily · oral · 12 weeksAs given in this study (human).
Measurements
Mean change from baseline in abdominal pain
−1.93 not stated
MD-7246 300 μg once daily
Mean change from baseline in abdominal pain
−2.01 not stated
Placebo
Source sentences
Summary
Among the 388 randomised patients, there was no significant difference in mean change from baseline in abdominal pain between the MD-7246 300 μg, 600 μg and 1200 μg groups and placebo (-1.93, -1.58, -1.95 and - 2.01, respectively; p > 0.05 for each group vs placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424501
02HumanRandomized controlled trialEfficacy outcome
In adults with IBS-D, MD-7246 changed abdominal pain by -1.58 versus -2.01 with placebo, without a significant difference (p > 0.05).
In plain wordsIn adults with IBS-D, pain decreased numerically less with MD-7246 than placebo, without a significant difference.
Peptide
Linaclotide
Outcome
IncreaseAbdominal pain change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
600 μg once daily · oral · 12 weeksAs given in this study (human).
Measurements
Mean change from baseline in abdominal pain
−1.58 not stated
MD-7246 600 μg once daily
Mean change from baseline in abdominal pain
−2.01 not stated
Placebo
Source sentences
Summary
Among the 388 randomised patients, there was no significant difference in mean change from baseline in abdominal pain between the MD-7246 300 μg, 600 μg and 1200 μg groups and placebo (-1.93, -1.58, -1.95 and - 2.01, respectively; p > 0.05 for each group vs placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424502
03HumanRandomized controlled trialEfficacy outcome
In adults with IBS-D, MD-7246 changed abdominal pain by -1.95 versus -2.01 with placebo, without a significant difference (p > 0.05).
In plain wordsIn adults with IBS-D, pain decreased numerically less with MD-7246 than placebo, without a significant difference.
Peptide
Linaclotide
Outcome
IncreaseAbdominal pain change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
1200 μg once daily · oral · 12 weeksAs given in this study (human).
Measurements
Mean change from baseline in abdominal pain
−1.95 not stated
MD-7246 1200 μg once daily
Mean change from baseline in abdominal pain
−2.01 not stated
Placebo
Source sentences
Summary
Among the 388 randomised patients, there was no significant difference in mean change from baseline in abdominal pain between the MD-7246 300 μg, 600 μg and 1200 μg groups and placebo (-1.93, -1.58, -1.95 and - 2.01, respectively; p > 0.05 for each group vs placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424503
04HumanRandomized controlled trialEfficacy outcome
In adults with IBS-D, MD-7246 abdominal pain responder rates were similar to or lower than placebo rates.
In plain wordsIn adults with IBS-D, MD-7246 pain response rates were similar to or lower than placebo rates.
Peptide
Linaclotide
Outcome
MixedAbdominal pain responder rates
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
300, 600 or 1200 μg once daily · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
The abdominal pain responder rates in the MD-7246 groups were similar to or lower than those in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424504
05HumanNon-randomized trialEfficacy outcome
In adults with IBS-D, all MD-7246 doses had minimal effects on bowel function.
In plain wordsIn adults with IBS-D, all MD-7246 doses had minimal effects on bowel function.
Peptide
Linaclotide
Outcome
Direction not reportedBowel function
Study
n: not reported in source
Outcome group
Bowel Function · Gastrointestinal
Studied dose
300, 600 or 1200 μg once daily · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
All doses of MD-7246 had a minimal effect on bowel function and were generally well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424505
06HumanNon-randomized trialSafety outcome
In adults with IBS-D, all MD-7246 doses were generally well tolerated.
In plain wordsIn adults with IBS-D, all MD-7246 doses were generally well tolerated.
Peptide
Linaclotide
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
300, 600 or 1200 μg once daily · oral · 12 weeksAs given in this study (human).
Source sentences
Summary
All doses of MD-7246 had a minimal effect on bowel function and were generally well tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, double-blind, phase 2 clinical trial enrolled adult patients with IBS-D (Rome IV criteria).
Summary · context
Patients were randomised to placebo or once-daily oral MD-7246 300, 600 or 1200 μg for 12 weeks.
Report a problemFND-3632424506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00460811

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc.n = 420Apr 2007 to Apr 2008

Irritable Bowel Syndrome With Constipation

Trial page ClinicalTrials.govUpdated 4 Feb 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.